A Phase II Evaluation Of Lapatinib (GW572016) (NCI-Supplied Agent, NSC #727989) In The Treatment Of Persistent Or Recurrent Endometrial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Endometrial cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 03 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Dec 2007 The expected completion date for this trial is 1 Oct 2009.